ESMO-ASIA 2023

Dec 1 - 3, 2023 | Singapore

The agents listed below are currently under investigation. Their safety and efficacy have not been established.

Poster

Safety and Pharmacokinetics (PK) of Vepdegestrant in Japanese Patients With Estrogen Receptor (ER)+/Human Epidermal Growth Factor Receptor 2 (HER2) Advanced Breast Cancer: Results From a Japanese Phase 1 Study

H Iwata et al.

VIEW MATERIAL

Poster

Global Phase 3 Studies Evaluating Vepdegestrant in Estrogen Receptor (ER)+/Human Epidermal Growth Factor Receptor 2 (HER2) Advanced Breast Cancer: VERITAC-2 and VERITAC-3

H Iwata et al.

VIEW MATERIAL